<DOC>
	<DOC>NCT02016625</DOC>
	<brief_summary>The primary objective of this trial is to investigate the effect of multiple-dose faldaprevir (FDV) on the single-dose pharmacokinetics of cyclosporine or tacrolimus</brief_summary>
	<brief_title>Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criteria: Healthy males or females subjects Age 18 to 50 years (incl.) Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.) Signed and dated written informed consent prior to admission to the study Exclusion criteria: Any finding in the medical examination (including blood pressure, pulse rate or ECG) deviating from normal and judged clinically relevant by the investigator. Systolic blood pressure (BP) less than 100 mmHg and more than 140 mmHg. Diastolic BP less than 60 mmHg and more than 90 mmHg. Pulse rate (PR) less than 50 bpm and more than 90 bpm. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease judged clinically relevant by the investigator Positive QuantiFERONTB Gold InTube</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>